acmefirewoodis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bounce today?
Thoughts?
$26.00?
Tapering $10 billion every month for the next eight months.
Gold will follow it down as will "NUGT".
Bottom?
The fall is just starting.
This isn't a one day event. It's a "taper trend".
Don't rule out another reverse split.
"NUGT" could end the year in the "teens".
.40 is actually down from .43.
Just saying!!!
End of day dump is coming. Same as yesterday.
Gold under a $1,000 is likely.
$23.52 close today sounds about right.
Buffet says to stay away from gold.
Take the time to research the company and you'll realize it offers substantial upside and is substantially undervalued.
It will be one of the top performing stocks in 2014.
IMHO.
Down almost 3%. Once it breaks below $1,200 can $1,100 be far behind?
$22.00 tomorrow appears quite possible.
Spreading out the tapering over an extended period was probably the worse thing that the Fed could have done for the price of gold.
A gradual tapering into 2015 doesn't offer much hope for gold.
Just saying!!!
Closing below $24.00 today?
More good news for $AMBS:
http://finance.yahoo.com/news/amarantus-licenses-manf-related-wolframs-110000068.html
Substantially undervalued at less than a dime. Zack's analyst, Jason Napadano, said it's a buy and worth four times its current share price. That was before yesterday's news.
Twitter: @AmarantusBio
Bear market for gold could continue through 2014. I wouldn't bet against triple digit gold prices towards the end of 2014.
Imagine gold at $850 again.
Just saying!!!
p.s. Can GSS continue to operate with gold below $1,000?
Add a few shares today. The word is finally getting out to the market.
Expect a continual stream of positive news over the next six weeks. J.P. Morgan Healthcare Conference and T.B.I. Conference at the U.N. will garner more exposure for the company.
Orphan indications for diabetes and Retinitis Pigmentosa and others to be announced.
Partnership news (Novartis?) could take it above .50.
Uplisting to the NASDAQ in the second quarter of 2014 is a reasonable time frame.
Top performing stock in 2014. Gerald as bio-tech C.E.O. of the year.
Twitter: @AmarantusBio
p.s. Zack's analyst, Jason Napadano, had a "BUY" rating on AMBS with a .20 price target prior to the news of the orphan indication for diabetes.
Bear market for gold could continue through 2014. I wouldn't bet against triple digit gold prices towards the end of 2014.
Imagine gold at $850 again.
Just saying!!!
p.s. Another reverse split for "NUGT"?
The share price will be in the .12-.15 range within six weeks or sooner.
"Patience is a virtue."
Twitter: @AmarantusBio
p.s. AMBS will be one of the top performing stocks of 2014. Take it to the bank.
Gold will decline to below the $1,100 level. It's in the plan.
"NUGT" to $22.00.
Watch and learn.
Below $25.00 by Friday.
Novartis.
Follow the company on Twitter: @AmarantusBio
The next C.E.O./Chairman's blog from Gerald will be very informative and should lay out a plan of action heading into 2014.
I still expect the up listing to the NASDAQ to occur in the second quarter of 2014.
Exciting times for the company and its shareholders.
2014 will be a very "Happy New Year"!!!
More positive news for the Fed to lean towards tapering.
Today's closing price? $26.25?
In a note published Tuesday, Macquarie analyst Pierre Vaillancourt cut IAMGOLD's (NYSE: IAG [FREE Stock Trend Analysis]) rating from Outperform to Neutral.
Vaillancourt commented that higher cost structure, delayed commercial output at Westwood, and the lack of growth will "hold back" shares over the next year. Although IAMGOLD's valuation is attractive among peers, the analyst noted that there is no catalyst over the next 12 months. Macquarie added that the recent dividend suspension raises questions on the capital need of the company and their ability to generate a return of capital and free cash flow at $1200 per ounce for gold.
Read more: http://www.benzinga.com/analyst-ratings/analyst-color/13/12/4162881/macquarie-downgraded-iamgold-due-to-lack-of-catalyst#ixzz2nmFXFNTU
Closing below $26.00 today appears inevitable.
Expecting C.E.O./Chairman's blog from Gerald outlining the plans for 2014 at any time.
Should be interesting.
Shares under a nickle are an early Christmas gift.
All IMHO.
Twitter: @AmarantusBio
.40 on Thursday a.m.?
Gold at $1,150 if the Fed tapers?
Reasonable ranges? Lower?
$23.00 on Thursday a.m.?
Gold at $1,150?
Reasonable range if the Fed tapers?
I don't see Amarantus listed for the One-Med Forum. I think they will be presenting at this one:
JP Morgan’s 32nd Annual Healthcare Conference will be held January 13-16, 2014 in San Francisco, California.
http://globalbiodefense.com/events/jp-morgan-32nd-annual-healthcare-conference/
I've spoken with the C.E.O. eight times and that is why I own shares in the company.
Zack's analyst, Jason Napadano, has met with him several times and Jason has a buy rating on the stock and a current price target of .20.
It's the first time Jason has recommended a penny stock.
Amarantus at LD Micro 6th Annual Conference, December 3, 2013
http://ir.stockpr.com/amarantus/videos/view/124/amarantus-at-ld-micro-6th-annual-conference-december-3-2013
The individuals that own shares for the long term believe that Gerald will succeed on a number of "fronts" and that LymPro and MANF hold the value that we think they do.
There are no guarantees when it comes to start-up biotechs but I've never seen another one with so much potential at such a low market cap.
2014 will be an exciting year.
All IMHO.
No reason to buy it today.
It could end the week below $20.00 depending on the Fed.
Just saying!!!
Zack's analyst, Jason Napadano, placed a "BUY" rating on AMBS with a current value of .20/share.
I think he's being too conservative.
AMBS (Amarantus Bioscience) is currently working with Becton Dickinson to develop its diagnostic test to detect early stage Alzheimer's. A potential $500,000,000 annual market.
The company's patented drug, MANF, already has an "orphan indication" to possibly treat Retinitis Pigmentosa which has the potential of a $15 billion dollar market. The company also has several other "orphan indications" for MANF which haven't been announced as to what diseases are involved.
With a market cap in the $28M range currently it is substantially undervalued.
IMHO
Wishful thinking.
At one point in time Amgen traded at the equivalent of seven cents on a split adjusted basis.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on AMBS's advisory board.
"AMBS" - "The next Amgen in its infancy for less than a nickle."
Uplisting to the NASDAQ planned for 2014.
Zack's Analyst - "BUY" Rating - Price target Offers 400% Upside
http://seekingalpha.com/article/1848901-amarantus-fundamentals-are-improving?source=yahoo
Amarantus Relocates Headquarters to Janssen Labs @QB3 Incubator in San Francisco
http://finance.yahoo.com/news/amarantus-relocates-headquarters-janssen-labs-153100892.html
"AMBS" - "The next Amgen in its infancy for less than a nickle."
Zack's Analyst - "BUY" Rating - Price target Offers 400% Upside
http://seekingalpha.com/article/1848901-amarantus-fundamentals-are-improving?source=yahoo
Amarantus Relocates Headquarters to Janssen Labs @QB3 Incubator in San Francisco
http://finance.yahoo.com/news/amarantus-relocates-headquarters-janssen-labs-153100892.html
Might I suggest a New Year's resolution for everyone still posting here as follows: "I will never again post on the IHub "BONZ" board and use the time that I would have spent posting there to do something constructive that will enrich my life."
The phrase,"beating a dead horse", is quite appropriate here. Take my advice and move on.
Best wishes for a "Merry Christmas" and a "Happy New Year" to everyone.
p.s. I can't believe that so many seemingly intelligent individuals that supposebly have no position in "BONZ" are still posting here.
What happened the last time it hit .84?
I still wouldn't buy it for the long term until it goes below .40.
IMHO.